SEC Form 4 · accession 0001214659-16-015226
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul F Truex
Officer — Executive Chairman · Director
Period of report
Dec 2, 2016
Accepted (ET)
Dec 6, 2016 · 9:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $9.48 | Dec 2, 2016 | J | 170,000 | D | — | Sep 17, 2025 | Common Stock | 170,000 | 0 | D |
| Stock option (right to buy)F2 | $9.48 | Dec 2, 2016 | J | 180,000 | D | — | Sep 17, 2025 | Common Stock | 180,000 | 0 | D |
Explanation of responses
- F1On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 170,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. The Option was to vest monthly over four years beginning December 30, 2014 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025.
- F2On December 2, 2016, the Reporting Person and the Company agreed to cancel a stock option to purchase 180,000 shares of common stock dated September 17, 2015 (the "Option"), which Option was previously reported on a Form 4 filed with the SEC on September 18, 2015. This Option was to vest monthly over four years beginning September 17, 2015 (the "Vesting Start Date"). The Option would have completely vested on the fourth anniversary of the Vesting Start Date and would have expired on September 17, 2025.